Búsqueda de Publicación - Prisma - Unidad de Bibliometría

Publicaciones en la fuente JOURNAL FOR IMMUNOTHERAPY OF CANCER

Tipo Año Título Fuente
Artículo2024Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial.JOURNAL FOR IMMUNOTHERAPY OF CANCER
Resumen congreso2022IL17-producing γδ T cells promote resistance to CDK4/6 inhibitors in HR+HER2- breast cancerJOURNAL FOR IMMUNOTHERAPY OF CANCER
Artículo2022Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapyJOURNAL FOR IMMUNOTHERAPY OF CANCER
Artículo2021Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survivalJOURNAL FOR IMMUNOTHERAPY OF CANCER
Artículo2021Circulating myeloid-derived suppressor cells and regulatory T cells as immunological biomarkers in refractory/relapsed diffuse large B-cell lymphoma: translational results from the R2-GDP-GOTEL trialJOURNAL FOR IMMUNOTHERAPY OF CANCER
Artículo2021Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trialJOURNAL FOR IMMUNOTHERAPY OF CANCER
Artículo2020Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trialJOURNAL FOR IMMUNOTHERAPY OF CANCER
Artículo2019Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitorsJOURNAL FOR IMMUNOTHERAPY OF CANCER
Artículo2018A randomized phase II clinical trial of dendritic cell vaccination following complete resection of colon cancer liver metastasis 11 Medical and Health Sciences 1112 Oncology and CarcinogenesisJOURNAL FOR IMMUNOTHERAPY OF CANCER
Artículo2018Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burdenJOURNAL FOR IMMUNOTHERAPY OF CANCER